Clincosm LogoSign in Get a demo

Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

Sponsor
University of Oklahoma (Other)
Overall Status
Completed
CT.gov ID
NCT00929565
Collaborator
(none)
10
Enrollment
1
Location
28
Duration (Months)
0.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway.

The investigators plan to measure these factors prior to and after bronchoscopy.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    10 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.
    Study Start Date :
    Jun 1, 2009
    Actual Primary Completion Date :
    Jun 1, 2010
    Actual Study Completion Date :
    Oct 1, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    Lung cancer

    Comparison between individuals with and without pulmonary malignancy

    Outcome Measures

    Primary Outcome Measures

      Secondary Outcome Measures

      1. Volume of blood loss during the procedure [1 day]

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years to 80 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Any patient scheduled to undergo bronchoscopy
      Exclusion Criteria:

      • Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000

      • Patients not scheduled to undergo bronchoalveolar lavage (BAL)

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 VA Medical Center Oklahoma City Oklahoma United States 73104

      Sponsors and Collaborators

      • University of Oklahoma

      Investigators

      • Principal Investigator: Jijo John, MD, University of Oklahoma

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Gary Kinasewitz, Principal Investigator, University of Oklahoma
      ClinicalTrials.gov Identifier:
      NCT00929565
      Other Study ID Numbers:
      • 14455
      First Posted:
      Jun 29, 2009
      Last Update Posted:
      Apr 9, 2012
      Last Verified:
      Apr 1, 2012
      Keywords provided by Gary Kinasewitz, Principal Investigator, University of Oklahoma
      hemoptysis
      Additional relevant MeSH terms:
      Hemoptysis

      Study Results

      No Results Posted as of Apr 9, 2012